Introduction
============

Epithelioid hemangioendothelioma (EHE) is a rare disease that was initially described by Weiss and Enzinger in 1982 ([@b1-ol-0-0-5643]). EHE develops from a malignant transformation of the vascular endothelium and is generally located in soft tissues and internal organs ([@b1-ol-0-0-5643]). Hepatic epithelioid hemangioendothelioma (HEH) is the most common type of EHE; forms of EHE in other organs, including the lungs, brain, spleen, bones, breast, heart and stomach have been reported only rarely ([@b2-ol-0-0-5643]--[@b6-ol-0-0-5643]). HEH is a rare sarcoma of the liver, which typically presents as a number of nodules and may be misdiagnosed as a metastatic carcinoma ([@b7-ol-0-0-5643],[@b8-ol-0-0-5643]). Additionally, HEH may recur locally and metastasize to distant organs ([@b8-ol-0-0-5643]); HEH has previously been considered an intermediate malignancy ([@b9-ol-0-0-5643]). However, the World Health Organization has previously categorized EHE as having full malignant potential ([@b10-ol-0-0-5643]). Therefore, it is crucial to identify the grade of malignancy and to distinguish HEH from other types of epithelioid vascular tumors, including epithelioid hemangioma and epithelioid angiosarcoma. However, due to the morphological similarities, it is challenging to differentiate these tumors solely using histological features ([@b7-ol-0-0-5643]). The current study focused on microRNAs (miRNAs) and performed miRNA profiling, in order to identify novel specific biomarkers for the accurate diagnosis of HEH.

Case report
===========

A 72-year-old female was referred to Kagawa University Hospital in 2014 (Kagawa, Japan) for further evaluation of epigastralgia. The patient had no significant medical history and no familial history of genetic disorders or cancers. Abdominal contrast computed tomography (CT) revealed a number of liver tumors ([Fig. 1A](#f1-ol-0-0-5643){ref-type="fig"}); multiple nodules with capsules located peripherally in the liver were apparent, with coarse calcification and peripheral enhancement following the administration of contrast medium. A liver biopsy and immunohistochemical staining revealed that the tumor cells were positive for factor VIII-associated antigen (FVIII-rAg), platelet endothelial cell adhesion molecule 1 (CD31) and human hematopoietic progenitor cell antigen (CD34), consistent with a diagnosis of HEH ([Fig. 1B](#f1-ol-0-0-5643){ref-type="fig"}). Primary antibodies against human FVIII-rAg (Dako, Tokyo, Japan), CD31 (Dako, JC70A, Tokyo, Japan), and CD34 (Leica Microsystems, Tokyo, Japan) were added to paraffin-embedded liver sections. Secondary antibodies, including ImmPRESS™ REAGENT Anti-Rat Ig and ImmPRESS™ REAGENT Anti-Rabbit Ig, were also used (Vector Laboratories, Inc., Burlingame, CA, USA) and incubated with a DAB Substrate kit (Vector Laboratories, Inc.).

The patient was treated with a partial ultrasonography-guided hepatectomy for the multiple HEHs. Currently the patient is still alive and has been relapse-free for 2 years post-surgery.

To elucidate the etiology of HEH, particularly the miRNA profiles, tissue samples obtained from three separate sections of normal and tumor tissues were analyzed. Total RNA was extracted from the human liver samples using the miRNeasy Mini kit (Qiagen, Inc., Venlo, Netherlands), according to the manufacturer\'s instructions. Following RNA measurement with an RNA 6000 Nano kit (Agilent Technologies, Santa Clara, CA, USA), the samples were labeled using a miRCURY Hy3 Power Labeling kit (Exiqon, Vedbaek, Denmark) and then hybridized onto a mouse miRNA Oligo chip (version 19; Toray Industries, Inc., Tokyo, Japan). Scanning was conducted with the 3D-Gene Scanner 3000 (Toray Industries, Inc.). The 3D-Gene extraction version 1.2 software (Toray Industries, Inc.) was used to read the raw intensities of the image. To determine changes in miRNA expression between normal tissue and tumor tissue samples, the raw data were analyzed via GeneSpringGX version 10.0 (Agilent Technologies, Inc., Tokyo, Japan).

A total of 14 miRNAs were significantly upregulated and 93 miRNAs were significantly downregulated in the tumor tissues, as compared with the normal tissues ([Table I](#tI-ol-0-0-5643){ref-type="table"}). Additionally, these data were organized using unsupervised hierarchical clustering and analysis of variance (ANOVA) functions in the GeneSpring software. Unsupervised hierarchical clustering was performed by using the clustering function (condition tree) with Pearson\'s correlation. Two-way ANOVA and asymptotic P-value computation without any error correction on the samples were performed to identify the miRNAs that varied most prominently across the different groups. The P-value cutoff was set as 0.05. In the present study, the miRNAs in tumor tissues clustered separately from those in normal tissues ([Fig. 2](#f2-ol-0-0-5643){ref-type="fig"}). The microarray data used in the present study were submitted as a complete data set to the NCBI Gene Expression Omnibus (no. GSE66794). Each expression of 107 miRNAs, which were statistically up-and down-regulated in HEH tissues, was analyzed as compared to that profile in angiosarcoma which exhibits a similar histology to HEH by using 'Sarcoma-microRNA Database'. The sarcoma miRNA expression database was accessed through <http://www.oncomir.umn.edu/>.

Of a total of 107 significantly upregulated and downregulated miRNAs identified in HEH, only miR-122-5p and miR-1290 demonstrated a differential expression pattern in angiosarcoma ([Table I](#tI-ol-0-0-5643){ref-type="table"}).

Discussion
==========

HEH is a rare hepatic, vascular, soft-tissue tumor with malignant potential; the incidence of HEH is \<1/100,000 ([@b11-ol-0-0-5643]). The majority of patients present with nonspecific symptoms. HEH was first identified incidentally by imaging, including ultrasonography and computed tomography ([@b12-ol-0-0-5643]). The etiological factors of HEH require further study; however, various risk factors have been identified, including oral contraceptives, alcohol, trauma, viral infections and chronic liver diseases ([@b11-ol-0-0-5643],[@b12-ol-0-0-5643]). Thorotrast (thorium dioxide) ([@b13-ol-0-0-5643]) and vinyl chloride ([@b14-ol-0-0-5643]) have also been reported as risk factors.

Laboratory findings, including biochemical examination of blood, are typically non-diagnostic in cases of EHE. Tumor markers, including α-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19--9 have a potential role in excluding the diagnosis of other hepatic neoplasms ([@b15-ol-0-0-5643],[@b16-ol-0-0-5643]). Examination of blood samples has revealed that an increase in alkaline phosphatase is the most frequently observed abnormality of HEH ([@b12-ol-0-0-5643]). Radiological studies, including CT, magnetic resonance imaging and angiography indicate that there are two subtypes of HEH: The nodular subtype manifests as multifocal nodules in the early stages of HEH, and these nodules grow and eventually coalesce, whereas the diffuse subtype manifests as large confluent masses preferentially involving the peripheral liver ([@b17-ol-0-0-5643]). In the present case, multiple nodules with capsules were observed, located peripherally in the liver, appearing with coarse calcification and peripheral enhancement when imaged using a contrast medium ([Fig. 1A](#f1-ol-0-0-5643){ref-type="fig"}).

A definitive diagnosis of HEH requires histopathological examination; the predominant histological features include nests and cords of epithelioid endothelial cells and the presence of intracytoplasmic lumina. CD31, CD34 and FVIII-rAg are established endothelial cell markers that are commonly used for the diagnosis of EHE ([@b18-ol-0-0-5643]). As shown in [Fig. 1B](#f1-ol-0-0-5643){ref-type="fig"}, the immunohistochemistry of HEH tissue samples revealed the presence of these endothelial markers.

EHE has previously been considered as an intermediate malignancy; however, the World Health Organization has now classified EHE as having full malignant potential ([@b9-ol-0-0-5643],[@b10-ol-0-0-5643]). The metastatic rate of EHE is \~25% and mortality occurs in \~15% of all cases ([@b1-ol-0-0-5643],[@b9-ol-0-0-5643]). By contrast, angiosarcoma of deep soft tissues metastasizes in \~50% of epithelioid angiosarcomas, and mortality occurs in over half of patients within a year of the diagnosis ([@b19-ol-0-0-5643]). Prognostic factors to distinguish the two biological subsets of tumors require further study to be identified.

In the present study, miRNA profiles were examined using tumor tissue samples and adjacent normal tissue samples to identify the distinguishing features of EHE and angiosarcoma. Unsupervised hierarchical clustering analysis using Pearson\'s correlation demonstrated that the tumor tissues clustered separately from the normal tissues ([Fig. 2](#f2-ol-0-0-5643){ref-type="fig"}). Of the 107 significantly upregulated and downregulated miRNAs identified in HEH, only miR-122-5p and miR-1290 demonstrated a differential expression pattern between HEH and angiosarcoma ([Table I](#tI-ol-0-0-5643){ref-type="table"}). miR-122-5p has previously been identified to be downregulated in patients with hepatocellular carcinoma, as compared with the healthy controls ([@b20-ol-0-0-5643]). The expression of miR-1290 has also previously been demonstrated to be associated with breast cancer prognosis ([@b21-ol-0-0-5643]). Interestingly, those previous reports indicate that miR-122-5p and miR-1290 were down-regulated in epithelial cancer cells. Therefore, the results of the present study suggest that EHE has similar miRNA expression patterns to epithelial cancer cells and that these expression patterns in EHE may form a different phenotype from that in angiosarcoma. In conclusion, miRNA profiling has potential as a novel biological diagnostic tool for HEH. Furthermore, miR-122-5p and miR-1290 are potential biomarkers for the accurate diagnosis of HEH in primary mesenchymal tumors of the liver.

![Clinicopathological features of the present case of hepatic epithelioid hemangioendothelioma. (A) Computed tomography revealed hypodense tumors in the two lobes (left panel). In the portal phase, the center of the tumor was enhanced in the right lobe (right panel; red arrow). (B) In the H&E-stained section, tumor cells were observed to form intracytoplasmic lumina, and solitary, alveolar and single-file patterns were detected. Immunohistochemical staining demonstrated that the tumor cells were positive for FVIII-rAg, CD31 and CD34. FVIII-rAg, factor VIII-associated antigen; CD31, platelet endothelial cell adhesion molecule 1; CD34, human hematopoietic progenitor cell antigen; H&E, hematoxylin and eosin.](ol-13-03-1655-g00){#f1-ol-0-0-5643}

![Hierarchical clustering of miRNAs between normal and tumor tissues. Liver tissue miRNA clustering was performed according to the expression profiles of 107 differentially expressed miRNAs between normal and tumor tissues. The analyzed tissue samples are presented in the columns and the miRNAs are presented in the rows. The miRNA-clustering tree is presented on the left and the sample-clustering tree is presented at the top. The color scale depicts the relative expression levels of the miRNAs in the patient tissue samples, with red representing a high expression level and blue representing a low expression level. miRNA, microRNA.](ol-13-03-1655-g01){#f2-ol-0-0-5643}

###### 

Comparison of miRNAs between normal and HEH tumor tissues (P\<0.01).

  A, Upregulated miRNAs                                                       
  ----------------------------------------------------------------- --------- ------------------------------
  hsa-miR-145-5p                                                    0.0059    26.4833±12.9514
  hsa-miR-155-5p                                                    0.0099    20.5192±8.659
  hsa-miR-181a-5p                                                   0.0071    13.1044±4.978
  hsa-miR-23b-3p                                                    0.0096    12.362±4.993
  hsa-miR-140-3p                                                    0.0076    12.7157±5.4437
  hsa-miR-125b-5p                                                   0.0056    11.0117±4.9514
  hsa-miR-4324                                                      0.0096    10.1675±4.1997
  hsa-miR-214-3p                                                    0.0056    12.0701±7.5642
  hsa-miR-26a-5p                                                    0.0058    10.9722±5.6222
  hsa-miR-126-3p                                                    0.0064    8.2668±3.5601
  hsa-miR-130b-3p                                                   0.0074    8.3378±4.1174
  hsa-miR-6822-5p                                                   0.0055    7.8268±3.3700
  hsa-let-7a-5p                                                     0.0058    5.2697±1.8241
  hsa-miR-34c-3p                                                    0.0043    1.6188±0.1349
                                                                              
  B, Downregulated miRNAs                                                     
                                                                              
  miRNA                                                             P-value   Fold change (T/N), mean ± SD
                                                                              
  hsa-miR-4463                                                      0.0076    0.5185±0.1658
  hsa-miR-4713-5p                                                   0.0049    0.4745±0.1267
  hsa-miR-3191-5p                                                   0.0090    0.4616±0.1886
  hsa-miR-296-3p                                                    0.0059    0.441±0.1595
  **hsa-miR-1290^[a](#tfn1-ol-0-0-5643){ref-type="table-fn"}^**     0.0089    0.4589±0.1978
  hsa-miR-6716-5p                                                   0.0066    0.4225±0.1967
  hsa-miR-4442                                                      0.0016    0.4199±0.1121
  hsa-miR-4534                                                      0.0056    0.4224±0.1531
  hsa-miR-4484                                                      0.0019    0.4176±0.1387
  hsa-miR-615-3p                                                    0.0065    0.3907±0.114
  hsa-miR-6791-5p                                                   0.0067    0.4044±0.1801
  hsa-miR-636                                                       0.0006    0.3943±0.0982
  hsa-miR-6808-5p                                                   0.0076    0.4024±0.143
  hsa-miR-4800-3p                                                   0.0039    0.3808±0.1669
  hsa-miR-6855-3p                                                   0.0022    0.3805±0.1372
  hsa-miR-4525                                                      0.0014    0.3655±0.0679
  hsa-miR-6165                                                      0.0053    0.3614±0.1487
  hsa-miR-7114-5p                                                   0.0065    0.3395±0.128
  hsa-miR-6879-5p                                                   0.0012    0.3438±0.1193
  hsa-miR-3622a-5p                                                  0.0078    0.3342±0.1694
  hsa-miR-4497                                                      0.0081    0.3358±0.1514
  hsa-miR-8089                                                      0.0024    0.3367±0.1433
  hsa-miR-6880-5p                                                   0.0025    0.3261±0.1262
  hsa-miR-7854-3p                                                   0.0068    0.3168±0.1401
  hsa-miR-6895-5p                                                   0.0027    0.316±0.1378
  hsa-miR-885-5p                                                    0.0080    0.3281±0.1762
  hsa-miR-7110-5p                                                   0.0078    0.3198±0.1633
  hsa-miR-6877-5p                                                   0.0062    0.3072±0.1433
  hsa-miR-3194-5p                                                   0.0050    0.3039±0.1679
  hsa-miR-1469                                                      0.0008    0.2858±0.1107
  hsa-miR-5010-5p                                                   0.0048    0.2964±0.1442
  hsa-miR-370-3p                                                    0.0043    0.2966±0.1479
  hsa-miR-4749-5p                                                   0.0099    0.3068±0.1709
  hsa-miR-6076                                                      0.0084    0.2912±0.1304
  hsa-miR-664b-5p                                                   0.0081    0.2968±0.1903
  hsa-miR-4745-5p                                                   0.0043    0.276±0.0822
  hsa-miR-3714                                                      0.0009    0.2668±0.0619
  hsa-miR-6824-5p                                                   0.0053    0.2791±0.0895
  hsa-miR-6825-5p                                                   0.0070    0.2823±0.1436
  hsa-miR-6889-5p                                                   0.0007    0.2673±0.1206
  hsa-miR-5585-3p                                                   0.0071    0.2779±0.1291
  hsa-miR-4428                                                      0.0023    0.2574±0.1187
  hsa-miR-184                                                       0.0069    0.2667±0.0888
  hsa-miR-642b-3p                                                   0.0068    0.2536±0.1318
  hsa-miR-3621                                                      0.0014    0.2451±0.0755
  hsa-miR-6769a-5p                                                  0.0045    0.2436±0.1112
  hsa-miR-1247-3p                                                   0.0002    0.2335±0.0803
  hsa-miR-6757-5p                                                   0.0074    0.2381±0.1004
  hsa-miR-1233-5p                                                   0.0009    0.2357±0.0937
  hsa-miR-8060                                                      0.0031    0.2276±0.0573
  hsa-miR-6825-3p                                                   0.0041    0.2303±0.0685
  hsa-miR-1254                                                      0.0050    0.2409±0.1457
  hsa-miR-3925-5p                                                   0.0096    0.248±0.0242
  hsa-miR-6851-5p                                                   0.0047    0.2196±0.1064
  hsa-miR-6748-5p                                                   0.0081    0.2358±0.1399
  hsa-miR-4257                                                      0.0071    0.2184±0.090
  hsa-miR-6743-5p                                                   0.0017    0.2173±0.0827
  hsa-miR-564                                                       0.0020    0.2139±0.0959
  hsa-miR-8063                                                      0.0060    0.2046±0.1137
  hsa-miR-1229-5p                                                   0.0044    0.2149±0.0950
  hsa-miR-6124                                                      0.0072    0.2171±0.1188
  hsa-miR-4792                                                      0.0006    0.1942±0.072
  hsa-miR-4476                                                      0.0019    0.2045±0.0877
  hsa-miR-4481                                                      0.0094    0.1983±0.0423
  hsa-miR-4435                                                      0.0025    0.1843±0.0804
  hsa-miR-3150a-3p                                                  0.0043    0.1788±0.0622
  **hsa-miR-122-5p^[a](#tfn1-ol-0-0-5643){ref-type="table-fn"}^**   0.0094    0.1912±0.0978
  hsa-miR-6750-5p                                                   0.0097    0.1705±0.0376
  hsa-miR-4498                                                      0.0011    0.1771±0.0938
  hsa-miR-6775-3p                                                   0.0038    0.167±0.0633
  hsa-miR-6870-5p                                                   0.0032    0.1774±0.0767
  hsa-miR-3682-3p                                                   0.0044    0.1664±0.0194
  hsa-miR-765                                                       0.0033    0.1515±0.081
  hsa-miR-8071                                                      0.0045    0.1602±0.0773
  hsa-miR-6782-5p                                                   0.0042    0.1646±0.0752
  hsa-miR-1236-5p                                                   0.0006    0.157±0.0564
  hsa-miR-7150                                                      0.0022    0.161±0.0669
  hsa-miR-4756-5p                                                   0.0024    0.1585±0.081
  hsa-miR-6891-5p                                                   0.0073    0.1647±0.0828
  hsa-miR-4638-3p                                                   0.0009    0.1561±0.0716
  hsa-miR-6769b-5p                                                  0.0031    0.1561±0.0639
  hsa-miR-6871-5p                                                   0.0022    0.1439±0.0416
  hsa-miR-4443                                                      0.0071    0.1427±0.0639
  hsa-miR-513a-5p                                                   0.0038    0.1287±0.0552
  hsa-miR-8078                                                      0.0061    0.1079±0.0482
  hsa-miR-6842-5p                                                   0.0012    0.0943±0.0427
  hsa-miR-194-5p                                                    0.0015    0.0948±0.0434
  hsa-miR-6893-5p                                                   0.0045    0.0858±0.0367
  hsa-miR-192-5p                                                    0.0016    0.0816±0.0414
  hsa-miR-3162-5p                                                   0.0063    0.0799±0.0308
  hsa-miR-4450                                                      0.0052    0.0558±0.0073
  hsa-miR-3678-3p                                                   0.0026    0.0546±0.0283
  hsa-miR-3649                                                      0.0045    0.0417±0.0192

miRNAs were differentially expressed in angiosarcoma compared with HEH. miRNA, microRNA; HEH, hepatic epithelioid hemangioendothelioma; T/N, tumor/normal tissue; SD, standard deviation.
